These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 25558950)

  • 1. Outcome measures for autoimmune blistering diseases.
    Zhao CY; Murrell DF
    J Dermatol; 2015 Jan; 42(1):31-6. PubMed ID: 25558950
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Measuring of quality of life in autoimmune blistering disorders in Poland. Validation of disease - specific Autoimmune Bullous Disease Quality of Life (ABQOL) and the Treatment Autoimmune Bullous Disease Quality of Life (TABQOL) questionnaires.
    Kalinska-Bienias A; Jakubowska B; Kowalewski C; Murrell DF; Wozniak K
    Adv Med Sci; 2017 Mar; 62(1):92-96. PubMed ID: 28208086
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of a quality-of-life instrument for autoimmune bullous disease: the Autoimmune Bullous Disease Quality of Life questionnaire.
    Sebaratnam DF; Hanna AM; Chee SN; Frew JW; Venugopal SS; Daniel BS; Martin LK; Rhodes LM; Tan JC; Wang CQ; Welsh B; Nijsten T; Murrell DF
    JAMA Dermatol; 2013 Oct; 149(10):1186-91. PubMed ID: 23925444
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessing the Correlation Between Disease Severity Indices and Quality of Life Measurement Tools in Pemphigus.
    Krain RL; Kushner CJ; Tarazi M; Gaffney RG; Yeguez AC; Zamalin DE; Pearson DR; Feng R; Payne AS; Werth VP
    Front Immunol; 2019; 10():2571. PubMed ID: 31781098
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Reliability, Validity and Responsiveness of Two Disease Scores (BPDAI and ABSIS) for Bullous Pemphigoid: Which One to Use?
    Wijayanti A; Zhao CY; Boettiger D; Chiang YZ; Ishii N; Hashimoto T; Murrell DF
    Acta Derm Venereol; 2017 Jan; 97(1):24-31. PubMed ID: 27244117
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Estimated cut-off values for pemphigus severity classification according to pemphigus disease area index (PDAI), autoimmune bullous skin disorder intensity score (ABSIS), and anti-desmoglein 1 autoantibodies.
    Mohebi F; Tavakolpour S; Teimourpour A; Toosi R; Mahmoudi H; Balighi K; Ghandi N; Ghiasi M; Nourmohammadpour P; Lajevardi V; Abedini R; Azizpour A; Nasimi M; Daneshpazhooh M
    BMC Dermatol; 2020 Oct; 20(1):13. PubMed ID: 33129291
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The development and validation of the treatment of autoimmune bullous disease quality of life questionnaire, a tool to measure the quality of life impacts of treatments used in patients with autoimmune blistering disease.
    Tjokrowidjaja A; Daniel BS; Frew JW; Sebaratnam DF; Hanna AM; Chee S; Dermawan A; Wang CQ; Lim C; Venugopal SS; Rhodes LM; Welsh B; Nijsten T; Murrell DF
    Br J Dermatol; 2013 Nov; 169(5):1000-6. PubMed ID: 24102329
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of autoimmune blistering diseases on work productivity.
    Wang EQ; Radjenovic M; Castrillón MA; Feng GHY; Murrell DF
    J Eur Acad Dermatol Venereol; 2018 Nov; 32(11):1959-1966. PubMed ID: 29730897
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessment of the quality of life of Egyptian and Tunisian autoimmune bullous diseases' patients using an Arabic version of the autoimmune bullous disease quality of life and the treatment of autoimmune bullous disease quality of life questionnaires.
    Saleh MA; Zaraa I; Doss N; Saleh NA; Murrell DF
    An Bras Dermatol; 2019; 94(4):399-404. PubMed ID: 31644610
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pemphigus disease activity measurements: pemphigus disease area index, autoimmune bullous skin disorder intensity score, and pemphigus vulgaris activity score.
    Rahbar Z; Daneshpazhooh M; Mirshams-Shahshahani M; Esmaili N; Heidari K; Aghazadeh N; Hejazi P; Ghajarzadeh M; Chams-Davatchi C
    JAMA Dermatol; 2014 Mar; 150(3):266-72. PubMed ID: 24429657
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Calculation of cut-off values based on the Autoimmune Bullous Skin Disorder Intensity Score (ABSIS) and Pemphigus Disease Area Index (PDAI) pemphigus scoring systems for defining moderate, significant and extensive types of pemphigus.
    Boulard C; Duvert Lehembre S; Picard-Dahan C; Kern JS; Zambruno G; Feliciani C; Marinovic B; Vabres P; Borradori L; Prost-Squarcioni C; Labeille B; Richard MA; Ingen-Housz-Oro S; Houivet E; Werth VP; Murrell DF; Hertl M; Benichou J; Joly P;
    Br J Dermatol; 2016 Jul; 175(1):142-9. PubMed ID: 26800395
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Beyond the skin: disease parameters in pemphigus.
    Viti G; Forcella C; Feliciani C; Murrell DF
    Ital J Dermatol Venerol; 2021 Apr; 156(2):147-150. PubMed ID: 33960750
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Objective scoring systems for disease activity in autoimmune bullous disease.
    Sebaratnam DF; Murrell DF
    Dermatol Clin; 2011 Jul; 29(3):515-20, xi. PubMed ID: 21605820
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical severity scores as a guide for prediction of initial treatment responses in pemphigus and pemphigoid patients.
    Tanaka R; Kurihara Y; Egami S; Saito Y; Ouchi T; Funakoshi T; Takahashi H; Umegaki-Arao N; Kubo A; Tanikawa A; Amagai M; Yamagami J
    J Dermatol; 2023 Feb; 50(2):203-211. PubMed ID: 35909336
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reliability of the autoimmune bullous disease quality of life (ABQOL) questionnaire in the USA.
    Sebaratnam DF; Okawa J; Payne A; Murrell DF; Werth VP
    Qual Life Res; 2015 Sep; 24(9):2257-60. PubMed ID: 25795375
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessing quality of life in patients with autoimmune bullous diseases using the Persian version of Treatment of Autoimmune Bullous Disease Quality of Life questionnaire finds similar effects in women as men.
    Behkar A; Garmaroudi G; Nasimi M; Yousefi S; Khosravi H; Kianfar N; Murrell DF; Daneshpazhooh M
    Int J Womens Dermatol; 2022 Mar; 8(1):e004. PubMed ID: 35620025
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oral health related qualıty of lıfe and dısease severıty ın autoımmune bullous dıseases.
    Bilgic A; Aydin F; Sumer P; Keskiner I; Koc S; Bozkurt S; Mumcu G; Alpsoy E; Uzun S; Akman-Karakas A
    Niger J Clin Pract; 2020 Feb; 23(2):159-164. PubMed ID: 32031089
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Validation studies of outcome measures in pemphigus.
    Hanna S; Kim M; Murrell DF
    Int J Womens Dermatol; 2016 Dec; 2(4):128-139. PubMed ID: 28492025
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical manifestations of alopecia in autoimmune blistering diseases: A cross-sectional study.
    Xie D; Bilgic A; Abu Alrub N; Dicle Ö; Murrell DF
    JAAD Int; 2023 Mar; 10():6-13. PubMed ID: 36387063
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Severity score indexes for blistering diseases.
    Daniel BS; Hertl M; Werth VP; Eming R; Murrell DF
    Clin Dermatol; 2012; 30(1):108-13. PubMed ID: 22137234
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.